Craig Coleman
Professor/Pharmacy Practice
Storrs Mansfield
Are you Craig Coleman?
How to update your information.
Scholarly Contributions
620 Scholarly Contributions
Comparison of VTE recurrence, bleeding-related hospitalization and all-cause mortality in patients with active cancer in two patient populations, based upon cancer types …
2023
Research Type: Poster/Presentation
OC 54.1 Effectiveness and Safety of Rivaroxaban and Low Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism: A Meta-Analysis of Oscar Programme Findings.
2023
Research Type: Poster/Presentation
Effectiveness of high-versus low-dose four-factor prothrombin complex concentrate on hemostasis and thromboembolism in patients with oral factor Xa inhibitor-associated
2023
Research Type: Poster/Presentation
PERSISTENCE OF REDUCED DOSE DOACS AND WARFARIN: A MULTINATIONAL COHORT STUDY OF INDIVIDUALS WITH INCIDENT AF
2023
Research Type: Poster/Presentation
2 Lower In-Hospital Mortality and Rebleeding Among Patients With Major Gastrointestinal Bleeding Treated With Andexanet Alfa vs 4-Factor Prothrombin Complex Concentrate. G Fermann, C Coleman, M Danese, E Lesén, M Christoph, R Chang,
2023
Research Type: Poster/Presentation
A Meta-Analysis of High-Dose Versus Low-Dose 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitor-Associated Intracerebral Hemorrhage
2023
Research Type: Poster/Presentation
A quality assessment of meta-analyses evaluating andexanet alfa and prothrombin complex concentrate (PCC) products.
2023
Research Type: Poster/Presentation
Using 30-Day Modified Rankin Scale Score to Predict 90-Day Values in Individuals With Intracerebral Hemorrhage
2023
Research Type: Poster/Presentation
OC 31.2 Andexanet Alfa is Associated with Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients with Factor Xa Inhibitor–Related Major
2023
Research Type: Poster/Presentation
A meta-analysis of high-dose versus low-dose 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitor-associated intracerebral hemorrhage
2023
Research Type: Poster/Presentation
Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills.
2022
Research Type: Journal Article
Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study.
2022
Research Type: Journal Article
Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
2022
Research Type: Journal Article
A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years.
2022
Research Type: Journal Article
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
2022
Research Type: Journal Article
Derivation and validation of the saved score for prediction of unfavorable modified Rankin scale score following intracerebral hemorrhage.
2022
Research Type: Poster/Presentation
Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer …
2022
Research Type: Poster/Presentation
Meta-Analysis and Meta-Regression to Assess Four-Factor Prothrombin Complex Concentrate's Ability to Achieve Hemostatic Effectiveness in Patients with Oral Factor Xa Inhibitor …
2022
Research Type: Poster/Presentation
Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism
2022
Research Type: Poster/Presentation